Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients

Medical Oncology

Volumn 32, Issue 2, 2015, Pages

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Cabiddu, Mary ^a   Borgonovo, Karen ^a   Lonati, Veronica ^a   Ghilardi, Mara ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Bevacizumab; Colorectal cancer; First line; Meta analysis; Prognostic factors

Indexed keywords

BEVACIZUMAB; LACTATE DEHYDROGENASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; META ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; MORTALITY; PROGNOSIS; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84920829728     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0456-z     Document Type: Review

References (46)

1. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75.
2. Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32:5 s (suppl; abstr LBA3).
3. Heinemann V, Modest D, von Weikersthal LF, et al. Independent radiological evaluation of objective response early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306). Ann Oncol. 2014;25:ii117.
4. Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol. 2013;8(3):173–81.
5. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97(13):981–9.
6. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308–17.
7. Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, Desramé J, Larsen AK, André T, Louvet C, de Gramont A. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist. 2011;16(9):1228–38.
8. Cai J, Ma H, Huang F, Zhu D, Bi J, Ke Y, Zhang T. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol. 2013;28(11):306.
9. Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W, Gao S. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig. 2013;33(11):779–88.
10. Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, Liu CY, Chen CZ, Liu YW. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One. 2013;8(6):e66721.
11. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305(5):487–94.
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J. 2009;339:b2535.
13. Cochrane handbook for systematic reviews of interventions. http://www.cochrane.org/training/cochrane-handbook. Accessed November 15th, 2013.
14. Aoyagi Y, Iinuma H, Horiuchi A, Shimada R, Watanabe T. Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6. Oncol Lett. 2010;1(2):253–9.
15. Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS. Tissue MicroRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line capecitabine and oxaliplatin with or without bevacizumab. PLoS One. 2014;9(10):e109430.
16. Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(10):2554–9.
17. Buchler T, Pavlik T, Melichar B, Bortlicek Z, Usiakova Z, Dusek L, Kiss I, Kohoutek M, Benesova V, Vyzula R, Abrahamova J, Obermannova R. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer. 2014;7(14):323.
18. Budai B, Komlósi V, Adleff V, Pap É, Réti A, Nagy T, Kralovánszky J, Láng I, Hitre E. Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI + bevacizumab. Pharmacogenet Genomics. 2012;22(1):69–72.
19. Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer. 2012;11(4):238–46.
20. Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isıkdogan A, Ozkan M, Coskun U, Buyukberber S. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents. Asian Pac J Cancer Prev. 2012;13(3):1059–63.
21. Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, Salvatore L, Cremolini C, Schirripa M, Graziano F, Ronzoni M, Ricci V, Farrar WL, Falcone A, Danesi R. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol. 2012;23(5):1207–13.
22. Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, C Fernández-Martos, Arrivi A, Bando I, Aranda E. Spanish Cooperative Group for the treatment of digestive Tumors (TTD). Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One. 2012;7(10):e47345.
23. Formica V, Luccchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, Tesauro M, Cereda V, Guadagni F, Roselli M. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol. 2014;31(9):166.
24. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011;17(17):5783–92.
25. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26(33):5326–34.
26. Guiu B, Petit JM, Bonnetain F, Ladoire S, Guiu S, Cercueil JP, Krausé D, Hillon P, Borg C, Chauffert B, Ghiringhelli F. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut. 2010;59(3):341–7.
27. Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M, Borg C. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013;27(13):611.
28. Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J. 2012;12(6):468–75.
29. Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med. 2013;54(12):2062–9.
30. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One. 2013;8(7):e66774.
31. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 2011;14(11):247.
32. Maillet M, Dréanic J, Dhooge M, Mir O, Brezault C, Goldwasser F, Chaussade S, Coriat R. The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab. Anti-cancer Drugs. 2014;25(10):1215–9.
33. Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, François E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol. 2012;23(4):919–27.
34. Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer. 2012;12:271.
35. Ryanne WuR, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009;40(3–4):101–8.
36. Sastre J, Vidaurreta M, Gómez A, Rivera F, Massutí B, López MR, Abad A, Gallen M, Benavides M, Aranda E, Rubio ED. Spanish cooperative group for the treatment of digestive tumors. prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer. 2013;12(4):280–6.
37. Slavicek L, Pavlik T, Tomasek J, Bortlicek Z, Buchler T, Melichar B, Vyzula R, Prausova J, Finek J, Majek O, Dusek L. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterol. 2014;25(14):53.
38. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–626; discussion 626–627.
39. Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell’aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, Tonini G. Dicer and Drosha expression and response to bevacizumab-based therapy in advanced colorectal cancer patients. Eur J Cancer. 2013;49(6):1501–8.
40. Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I, Franco D, Ruggeri EM. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Invest New Drugs. 2013;31(4):1035–43.
41. Matsusaka S, Suenaga M, Mishima Y, Takagi K, Terui Y, Mizunuma N, Hatake K. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2011;68(3):763–8.
42. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Barni S. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol. 2013;30(3):650.
43. Silvestris N, Scartozzi M, Graziano G, et al. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther. 2014;19:1–8.
44. Azuma M, Shi M, Danenberg KD, et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007;8:1705–13.
45. Petrelli F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol. 2013;24(1):186–92.
46. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, Lv Y. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134(10):2403–13.